The Canadian Methotrexate and Etanercept Outcome Study: a randomised trial of discontinuing versus continuing methotrexate after 6 months of etanercept and methotrexate therapy in rheumatoid arthritis

Conclusions
Non-inferiority was not achieved. Withdrawing MTX after 6 months of continuation ETN+MTX in MTX inadequate responders did not yield the same degree of improvement between 6 and 12 months compared with continuing ETN+MTX.

Trial Registration
ClinicalTrials.gov–NCT00654368.

Source: Annals of the Rheumatic Diseases - October 30, 2014 Category: Rheumatology Authors: Pope, J. E., Haraoui, B., Thorne, J. C., Vieira, A., Poulin-Costello, M., Keystone, E. C. Tags: Open access, Immunology (including allergy), Connective tissue disease, Degenerative joint disease, Musculoskeletal syndromes, Rheumatoid arthritis, Epidemiology Clinical and epidemiological research Source Type: research